Status:
COMPLETED
Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-99 years
Brief Summary
Pilot observational study to describe the relationship between the smoking status of a psoriatic individual and the success of etanercept therapy in psoriasis treatment
Detailed Description
non-interventional study There is no sampling
Eligibility Criteria
Inclusion
- Clinical diagnosis of chronic plaque type psoriasis for at least 6 months as determined by the subjects medical history, and confirmation of the diagnosis through physical examination by the investigator Patients who are scheduled by their dermatologist to initiate treatment with Etanercept
Exclusion
- Previous or current treatment with antipsoriatic biologic drugs, such as etanercept, infliximab, adalimumab, ustekinumab, alefacept, efalizumab Chronic or acute infections requiring intravenous or oral anti-infectives within 14 days prior to the Baseline visit
Key Trial Info
Start Date :
November 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT02192164
Start Date
November 1 2013
End Date
May 1 2016
Last Update
June 28 2017
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Semmelweis University
Budapest, Hungary, H-1085
2
Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum/Bor- es Nemikortani Klinika
Debrecen, Hungary, 4032
3
Somogy Megyei Kaposi Mór Oktató Kórház
Kaposvár, Hungary, H-7400
4
Bacs-Kiskun Megyei Onkormanyzat Korhaza Szegedi Tudomanyegyetem AOK Oktato Korhaza
Kecskemét, Hungary, 6000